A randomised phase I study of etrolizumab (rhuMab beta7) in moderate to severe ulcerative colitis. Gut 2013; 62: 1122-1130.

Published: 3rd October 2013

Authors: Rutgeerts PJ, Fedorak RN, Hommes DW, Sturm A, Baumgart DC, Bressler B et al. et al.

Conclusion

This dose-ranging study included 43 patients. In the group of 18 patients that had multiple doses, two thirds had a clinical response, and three had clinical remission.

Pubmed Link

Your comments

0 Comments